An even greater effort has been made to establish the proteins interacting with BACE1 as it is the BACE1 cleavage of APP that is the rate-limiting step in Aβ production [9], and BACE1 is a potential therapeutic target for AD. This evidence concerns the gene APP and Alzheimer disease.